Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Summary

The primary purpose of this study was to evaluate the safety and tolerability of intravenous (IV) ALXN1007 in persistently antiphospholipid (aPL)-positive patients with at least 1 of the following non-criteria manifestations of APS: aPL-nephropathy, skin ulcers and/or thrombocytopenia.

Timeline

Start

2014-04

Primary completion

2016-06

Completion

2016-06

Outcome

Outcome not reported

Stopped (Enrollment): “Screening discontinued early due to slow patient enrollment”

Drugs

Indications